Einzeltreffer — DigiBib

As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy.

Titel:	TRIMEGESTONE (TMG) FOR TREATMENT OF PRETERM BIRTH
Link:	Zum Volltext
Veröffentlichung:	2014
Medientyp:	Patent
Sonstiges:	Nachgewiesen in: USPTO Patent Applications Sprachen: English Document Number: 20140141102 Publication Date: May 22, 2014 Appl. No: 13/880031 Application Filed: October 27, 2011 Assignees: DIGNITY HEALTH (Phoenix, AZ, US) Claim: 1. A method of extending pregnancy term in a subject in need thereof, comprising: providing a quantity of a composition comprising a 19-norprogesterone, or a pharmaceutical equivalent, derivative, analog, and/or salt thereof; and administering the quantity of the composition to the subject in need thereof. Claim: 2. The method of claim 1, wherein the 19-norprogesterone comprises a compound of the formula: [chemical expression included] or a pharmaceutical equivalent, derivative, analog, and/or salt thereof. Claim: 3. The method of claim 1, wherein the composition further comprises one or more solubilizing factors. Claim: 4. The method of claim 3, wherein the one or more solubilizing factors is selected from the group consisting of: cyclodextrins, sesame oil, fish oil, corn oil, olive oil, coconut oil, krill oil, omega fatty acids, mineral oil, peppermint oil, flaxseed oil, vitamin E oil, argan oil, saline solution and glucose solution. Claim: 5. The method of claim 1, wherein the composition is administered through nasal, oral, subcutaneous, transmucosal, transdermal, parenteral, implantable pump, continuous infusion, topical, intradermal, intravenous, intramuscular, intraperitoneal, inhalation, rectal, non-vaginal and/or vaginal delivery. Claim: 6. The method of claim 1, further comprising administering of one or more compounds selected from the group consisting of: nifedipine, indomethacin, magnesium sulfate, oxytocin antagonists, and tocolytics. Claim: 7. The method of claim 6, wherein the one or more compounds is administered after administering the quantity of the composition comprising a 19-norprogesterone, or a pharmaceutical equivalent, derivative, analog, and/or salt thereof. Claim: 8. The method of claim 1, wherein the composition is administered at least twice daily. Claim: 9. The method of claim 1, wherein the composition is administered to the subject in the range of: 0.01-0.1 mg, 0.1-0.5 mg 0.5-1 mg, 1-5 mg, 5-10 mg, 10-15 mg, 15-20 mg, and/or 20-100 mg. Claim: 10. The method of claim 1, wherein the pregnancy term is at least 22 weeks. Claim: 11. The method of claim 1, wherein the pregnancy term is at least 37 weeks. Claim: 12. A pharmaceutical composition, comprising a therapeutically effective amount of a 19-norprogesterone, or a pharmaceutical equivalent, derivative, analog, and/or salt thereof, and a pharmaceutically acceptable carrier. Claim: 13. The pharmaceutical composition of claim 12, wherein the 19-norprogesterone comprises a compound of the formula: [chemical expression included] or a pharmaceutical equivalent, derivative, analog, and/or salt thereof. Claim: 14. The pharmaceutical composition of claim 12, wherein the composition further comprises one or more solubilizing factors. Claim: 15. The pharmaceutical composition of claim 14, wherein the one or more solubilizing factors is selected from the group consisting of cyclodextrins, sesame oil, fish oil, corn oil, olive oil, coconut oil, krill oil, omega fatty acids, mineral oil, peppermint oil, flaxseed oil, vitamin E oil, argan oil, saline solution and glucose solution. Claim: 16. The pharmaceutical composition of claim 12, further comprising one or more compounds selected from the group consisting of: nifedipine, indomethacin, magnesium sulfate, oxytocin antagonists, and tocolytics. Claim: 17. The pharmaceutical composition of claim 12 provided in a dosage in the range of: 0.01-0.1 mg, 0.1-0.5 mg 0.5-1 mg, 1-5 mg, 5-10 mg, 10-15 mg, 15-20 mg, and/or 20-100 mg. Claim: 18. A method of treating a disease and/or condition in a subject in need thereof, comprising: providing a quantity of a composition comprising a 19-norprogesterone, or a pharmaceutical equivalent, derivative, analog, and/or salt thereof; and administering the quantity of the composition to the subject in need thereof. Claim: 19. The method of claim 18, wherein the 19-norprogesterone comprises a compound of the formula: [chemical expression included] or a pharmaceutical equivalent, derivative, analog, and/or salt thereof. Claim: 20. The method of claim 18, wherein the composition further comprises one or more solubilizing factors. Claim: 21. The method of claim 20, wherein the one or more solubilizing factors is selected from the group consisting of: cyclodextrins, sesame oil, fish oil, corn oil, olive oil, coconut oil, krill oil, omega fatty acids, mineral oil, peppermint oil, flaxseed oil, vitamin E oil, argan oil, saline solution and glucose solution. Claim: 22. The method of claim 18, wherein the composition is administered through nasal, oral, subcutaneous, transmucosal, transdermal, parenteral, implantable pump, continuous infusion, topical, intradermal, intravenous, intramuscular, intraperitoneal, inhalation, rectal, non-vaginal and/or vaginal delivery. Claim: 23. The method of claim 18, wherein composition further comprises administering one or more compounds selected from the group consisting of: nifedipine, indomethacin, magnesium sulfate, oxytocin antagonists, and tocolytics. Claim: 24. The method of claim 23, wherein the one or more compounds is administered after administering the quantity of the composition comprising a 19-norprogesterone, or a pharmaceutical equivalent, derivative, analog, and/or salt thereof. Claim: 25. The method of claim 18, wherein the composition is administered twice daily. Claim: 26. The method of claim 18, wherein the composition is administered to the subject in the range of 0.01-0.1 mg, 0.1-0.5 mg 0.5-1 mg, 1-5 mg, 5-10 mg, 10-15 mg, 15-20 mg, and/or 20-100 mg. Claim: 27. The method of claim 18, wherein the disease and/or condition is selected from the group consisting of: preterm labor, term labor, luteal insufficiency, dysmenorrhea, dysfunctional uterine bleeding, and combinations thereof. Claim: 28. The method of claim 27, wherein the disease and/or condition is dysmenorrhea. Claim: 29. The method of claim 27, wherein the disease and/or condition is luteal insufficiency. Current U.S. Class: 424/682 Current International Class: 61; 61; 61; 61; 61; 61; 61

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

TRIMEGESTONE (TMG) FOR TREATMENT OF PRETERM BIRTH